Role of autologous stem cell transplantation in multiple myeloma

被引：0

作者：

Kumar S. ^{[1
]}

机构：

[1] Division of Hematology, Mayo Clinic, Rochester, MN 55905, First Street SW

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 2期

关键词：

Overall Survival; Multiple Myeloma; Thalidomide; Bortezomib; Lenalidomide;

D O I：

10.1007/s11899-007-0017-z

中图分类号：

学科分类号：

摘要：

High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achieve a very good response to initial transplantation. Other randomized trials, as well as smaller phase II trials and retrospective studies, have allowed us to improve the process of ASCT in terms of the stem cell collection, conditioning regimens, and extension of the therapy to a wider patient population. The introduction of thalidomide, lenalidomide, and bortezomib have changed the paradigm for treatment of myeloma and significantly improved the outcome for these patients. The role of ASCT will clearly be redefined in the coming years with improvements in other therapies. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：121 / 127

页数：6

共 42 条

[1]

McElwain T.J., Powles R.L., High-dose intravenous melphalan for plasma-cell leukaemia and myeloma, Lancet, 2, pp. 822-824, (1983)

[2]

Selby P., Zulian G., Forgeson G., Et al., The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St. Bartholomew's Hospital studies, Hematol Oncol, 6, pp. 173-179, (1988)

[3]

Barlogie B., Alexanian R., Dicke K.A., Et al., High-dose chemo radiotherapy and autologous bone marrow transplantation for resistant multiple myeloma, Blood, 70, pp. 869-872, (1987)

[4]

Harousseau J.L., Attal M., The role of stem cell transplantation in multiple myeloma, Blood Rev, 16, pp. 245-253, (2002)

[5]

Child J.A., Morgan G.J., Davies F.E., Et al., Medical Research Council Adult Leukaemia Working Party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 348, pp. 1875-1883, (2003)

[6]

Barlogie B., Kyle R.A., Anderson K.C., Et al., Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321, J Clin Oncol, 24, pp. 929-936, (2006)

[7]

Blade J., Rosinol L., Sureda A., Et al., High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA, Blood, 106, pp. 3755-3759, (2005)

[8]

Palumbo A., Bringhen S., Petrucci M.T., Et al., Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial, Blood, 104, pp. 3052-3057, (2004)

[9]

Fermand J.P., Ravaud P., Chevret S., Et al., High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial, Blood, 92, pp. 3131-3136, (1998)

[10]

Siegel D.S., Desikan K.R., Mehta J., Et al., Age is not a prognostic variable with autotransplants for multiple myeloma, Blood, 93, pp. 51-54, (1999)

← 1 2 3 4 5 →